Canada joins global heart disease
MONTREAL – CLARIFY, the largest
international registry to ever be carried out in stable coronary artery
disease (CAD) patients, was launched in 40 countries, including Canada,
at the European Society of Cardiology (ESC) Congress.
The CLARIFY registry (ProspeCtive observational LongitudinAl RegIstry oF
patients with stable coronary arterY disease) is designed to increase
knowledge and understanding of CAD and will provide important
epidemiological and clinical data, including an assessment of the role
of heart rate in the prognosis of CAD patients.
Coronary artery disease remains the leading cause of death worldwide.
Improved understanding of the management and outcomes of these patients
is paramount to reducing the disease burden.
Data available today on the presentation and management of CAD stem
mainly from randomized clinical trials or registries which have limited
generalisability due to the stringent selection process of participants
or the focus on a particular manifestation of the disease. There are
only limited contemporary data regarding stable outpatients with CAD,
their management and outcomes.
CLARIFY is a prospective, observational, longitudinal registry of stable
coronary artery disease (CAD) outpatients. The registry will be
representative of CAD patients seen by cardiologists and primary care
physicians in daily clinical practice. A minimum of 30,000 outpatients
with stable CAD from around 40 countries worldwide will be followed up
for five years. Data will be collected prospectively at annual visits
(12, 24, 36, 48 and 60 months). The overall aim of CLARIFY is to
characterize contemporary CAD patients in terms of their demographic
characteristics, clinical profiles, management and outcomes. CLARIFY
will also determine long-term prognostic factors in this group of
patients with a view to developing a powerful and comprehensive risk
prediction model, including all potential prognostic factors, including
resting heart rate. The CLARIFY registry is funded by an educational
grant from Servier Research Group, an independent pharmaceutical
company. Data will be collected and analyzed at the Robertson Centre for
Biostatistics, Glasgow, UK, under the guidance of Prof Ian Ford, and the
study is led by an executive steering committee composed of
international experts in the field of CAD.
About Coronary Artery Disease
Coronary artery disease (CAD) is the most common manifestation of
cardiovascular disease. It refers to the hardening and shrinking of the
coronary arteries (atherosclerosis) which leads to diminished blood flow
and reduces oxygen supply to the heart muscle (ischemia). The lack of
oxygen supply to the heart muscle may cause angina (chest pain).
If the coronary artery becomes completely blocked, a whole section of
the heart muscle is deprived of oxygen and dies, resulting in a
myocardial infarction (MI) or heart attack. Coronary artery disease is a
progressive, often silent disease that is most often unobserved until
the first symptoms of ischemia or MI occur. Although the prognosis of
patients with CAD has been greatly improved by advances in
cardiovascular treatment, it is still the most frequent cause of death.
Cardiovascular disease accounts for the death of more Canadians than any
other disease. In fact, in Canada someone dies every seven minutes from
it. According to the latest statistics available from Statistics Canada,
in 2005 cardiovascular disease accounted for close to one third of all
deaths in Canada (more than 71,000 deaths).
About Servier Canada Inc.
Servier Canada Inc. (www.servier.ca)
is a pharmaceutical company, based in Laval (Quebec) that focuses on the
development of therapies to treat cardiovascular, metabolic and central
nervous system diseases. It is the Canadian subsidiary of the Servier
Research Group, the leading French-based independent (private)
pharmaceutical company, which is present in 140 countries around the
world. The Servier Research Group distinguishes itself by investing 25
percent of its income in research and development, which is
approximately double the industry average. This enables the advancement
of scientific knowledge and the discovery of therapeutic innovations
leading to improved patient care and treatment outcomes.